Navigating CHPW Trelegy Prior Authorization: A Workflow Guide

Understanding CHPW's Prior Authorization Framework for Pharmacy Benefits

Community Health Plan of Washington (CHPW) implements prior authorization requirements for specific medications, including certain respiratory drugs, to ensure medical necessity and appropriate utilization. These requirements are determined by their Pharmacy and Therapeutics (P&T) Committee and are outlined in their formulary and clinical policies. For pharmacy benefits, CHPW's criteria often align with evidence-based guidelines, requiring documentation of specific diagnoses, prior treatment failures, or contraindications to alternative therapies.

Trelegy Ellipta: Clinical Indications and CHPW's Criteria

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a triple therapy indicated for the maintenance treatment of COPD and asthma. CHPW's prior authorization criteria for Trelegy typically focus on documented clinical need, often requiring confirmation of diagnosis via spirometry and a history of inadequate response or intolerance to less complex or preferred therapies. This may include trials of dual bronchodilators (LAMA/LABA) or inhaled corticosteroids (ICS)/LABA combinations, consistent with standard step therapy protocols for chronic respiratory conditions. Documentation must clearly articulate the patient's clinical presentation, disease severity, and rationale for Trelegy over other formulary options.

Submission Pathways for CHPW Trelegy Prior Authorization

CHPW offers several methods for submitting prior authorization requests for pharmacy benefits. Electronic prior authorization (ePA) through platforms like CoverMyMeds or Surescripts remains the most efficient pathway, leveraging the NCPDP SCRIPT standard for prescription and PA data exchange. Direct submission via CHPW's provider portal or through common payer portals like Availity may also be available, often utilizing a structured web form. Faxing dedicated CHPW prior authorization forms is another option, though it carries higher administrative burden and slower turnaround times. Phone submissions are generally reserved for urgent requests or status inquiries.

Key Documentation Requirements for Trelegy PA

Accurate and comprehensive documentation is paramount for a successful CHPW Trelegy prior authorization. Missing or unclear information is a primary cause of delays and denials. Prior authorization coordinators must ensure all necessary clinical and administrative data are compiled before submission. This includes specific patient demographics, the prescribing provider's details, and the complete medication order (NDC, dose, frequency, duration). Clinical notes must support the diagnosis and demonstrate adherence to CHPW's medical necessity criteria.

Essential Documentation Checklist for Trelegy PA

• Patient's full name, date of birth, and CHPW member ID.
• Prescribing provider's NPI, contact information, and signature.
• Primary and secondary ICD-10 diagnosis codes (e.g., J44.9 for COPD, J45.909 for Asthma).
• Specific drug name (Trelegy Ellipta), strength, dosage form, route, and frequency.
• Quantity and days' supply requested.
• Clinical notes detailing patient's history of present illness, relevant physical exam findings.
• Spirometry results (FEV1, FEV1/FVC ratio) supporting diagnosis and severity.
• Documentation of failed trials or contraindications to at least two other formulary-preferred respiratory medications (e.g., LAMA/LABA, ICS/LABA).
• Patient's current and past medication history relevant to respiratory conditions.

Navigating Denials and the Appeals Process

Despite diligent preparation, CHPW Trelegy prior authorization requests may face denial. Common reasons include incomplete documentation, failure to meet clinical criteria, or formulary restrictions. Upon denial, a thorough review of the denial letter is essential to understand the specific reason. The appeals process typically begins with an internal appeal, often requiring additional clinical information or a peer-to-peer (P2P) discussion between the prescribing provider and a CHPW medical director. If the internal appeal is unsuccessful, an external review by an independent third party may be pursued, adhering to state and federal regulations.

Integrating PA Workflows within EHR Systems

Modern EHR systems like Epic Hyperspace and Cerner PowerChart offer capabilities to integrate prior authorization workflows, reducing manual data entry and improving tracking. Utilizing SMART on FHIR applications or leveraging the Da Vinci PAS implementation guide can facilitate automated data retrieval from the patient's chart to populate ePA forms. This integration minimizes the administrative burden associated with CHPW Trelegy prior authorization by ensuring discrete data elements are readily accessible and transferable. Consistent use of structured data entry within the EHR supports more efficient PA submissions.

Best Practices for Efficient CHPW Trelegy PA Management

Optimizing the CHPW Trelegy prior authorization process requires a systematic approach. Proactive eligibility and benefit verification are foundational steps to identify PA requirements early. Implementing standardized internal checklists for documentation ensures consistency and completeness across all submissions. Regular training for prior authorization teams on CHPW's specific criteria and submission portals helps maintain proficiency. Leveraging technology for real-time status checks and analytics can identify bottlenecks and inform process improvements, ultimately reducing turnaround times and improving approval rates.